Treatment - The Journal of Clinical Endocrinology & Metabolism

J Clin Endocrinol Metab, October 2009, 94(10):3700–3707 jcem.endojournals.org 3707
treatment of hyperthyroidism: significance of effective half-life measurements.
J Nucl Med 37:228–232
11. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML,
Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A,
Rossi G, Martino E, Pinchera A 1998 Relation between therapy for
hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl
J Med 338:73–78
12. Gamstedt A, Wadman B, Karlsson A 1986 Methimazole, but not
Betamethasone, prevents iodine-131 treatment-induced rises in thyrotropin
receptor autoantibodies in hyperthyroid Graves’ disease.
J Clin Endocrinol Metab 62:773–777
13. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell
G, Tørring O 2008 TSH-receptor autoimmunity in Graves’ disease
after therapy with anti-thyroid drugs, surgery, or radioiodine: a
5-year prospective randomized study. Eur J Endocrinol 158:69–75
14. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder
AE, Jyonouchi SC, Bahn RS 1999 Differentiation of human orbital
preadipocyte fibroblasts induces expression of functional thyrotropin
receptor. J Clin Endocrinol Metab 84:2557–2562
15. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS 2002 Stimulation
of adipogenesis, peroxisome proliferator-activated receptor-�
(PPAR�), and thyrotropin receptor by PPAR� agonist in human
orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 87:2352–
2358
16. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ 2003
Immunoglobulin activation of T cell chemoattractant expression in
fibroblasts from patients with Graves’ disease is mediated through
the insulin-like growth factor I receptor pathway. J Immunol 170:
6348–6354
17. Smith TJ, Hoa N 2004 Immunoglobulins from patients with Graves’
disease induce hyaluronan synthesis in their orbital fibroblasts
through the self-antigen, insulin-like growth factor-I receptor. J Clin
Endocrinol Metab 89:5076–5080
18. Tötterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I 1987
Induction of circulating activated suppressor-like T cells by methimazole
therapy for Graves’ disease. N Engl J Med 316:15–22
19. Weetman AP, Holt ME, Campbell AK, Hall R, McGregor AM 1984
Methimazole and generation of oxygen radicals by monocytes: potential
role in immunosuppression. Br Med J (Clin Res Ed) 288:
518–520
20. Hallengren B, Forsgren A, Melander A 1980 Effects of antithyroid
drugs on lymphocyte function in vitro. J Clin Endocrinol Metab
51:298–301
21. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR,
Hall R 1980 Carbimazole and the autoimmune response in Graves’
disease. N Engl J Med 303:302–307
22. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor
P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò
N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH,
Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz
S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008
Consensus Statement of the European Group on Graves’ Orbitopathy
(EUGOGO) on Management of Graves’ Orbitopathy. Thyroid
18:333–346
23. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor
P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò
N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH,
Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz
S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM; European
Group on Graves’ Orbitopathy (EUGOGO) 2008 Consensus Statement
of the European Group on Graves’ Orbitopathy (EUGOGO)
on Management of Graves’ Orbitopathy. Eur J Endocrinol 158:
273–285.
24. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera
A 1989 Use of corticosteroids to prevent progression of Graves’
ophthalmopathy after radioiodine therapy for hyperthyroidism.
N Engl J Med 321:1349–1352
25. Dederichs B, Dietlein M, Jenniches-Kloth B, Schmidt M, Theissen P,
Moka D, Schicha H 2006 Radioiodine therapy of Graves’ hyperthyroidism
in patients without pre-existing ophthalmopathy: can
glucocorticoids prevent the development of new ophthalmopathy?
Exp Clin Endocrinol Diabetes 114:366–370
26. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J 2005 A
prospective study of the effects of radioiodine therapy for hyperthyroidism
in patients with minimally active graves’ ophthalmopathy.
J Clin Endocrinol Metab 90:5321–5323
27. Sisson JC, Schipper MJ, Nelson CC, Freitas JE, Frueh BR 2008
Radioiodine therapy and Graves’ ophthalmopathy. J Nucl Med 49:
923–930
28. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen
S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor
autoantibodies are independent risk factors for Graves’ ophthalmopathy
and help to predict severity and outcome of the disease.
J Clin Endocrinol Metab 91:3464–3470
29. Wiersinga WM 2007 Management of Graves’ ophthalmopathy. Nat
Clin Pract Endocrinol Metab 3:396–404